Related Experiment Video
Updated: Nov 24, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by Ataxia Telangiectasia and Rad3-Related
Tomas Goncalves1,2, Georgia Zoumpoulidou3, Carlos Alvarez-Mendoza3
1Centre for Genome Engineering and Maintenance, College of Health, Medicine and Life Sciences, Brunel University London, London UB8 3PH, United Kingdom.
Abstract:
To avoid replicative senescence or telomere-induced apoptosis, cancers employ telomere maintenance mechanisms (TMMs) involving either the upregulation of telomerase or the acquisition of recombination-based alternative telomere lengthening (ALT). The choice of TMM may differentially influence cancer evolution and be exploitable in targeted therapies. Here, we examine TMMs in a panel of 17 osteosarcoma-derived cell lines, defining three separate groups according to TMM and the length of telomeres maintained. Eight were ALT-positive, including the previously uncharacterized lines, KPD and LM7. While ALT-positive lines all showed excessive telomere length, ALT-negative cell lines fell into two groups according to their telomere length: HOS-MNNG, OHSN, SJSA-1, HAL, 143b, and HOS displayed subnormally short telomere length, while MG-63, MHM, and HuO-3N1 displayed long telomeres. Hence, we further subcategorized ALT-negative TMM into long-telomere (LT) and short-telomere (ST) maintenance groups. Importantly, subnormally short telomeres were significantly associated with hypersensitivity to three different therapeutics targeting the protein kinase ataxia telangiectasia and Rad3-related (ATR) (AZD-6738/Ceralasertib, VE-822/Berzoserib, and BAY-1895344) compared to long telomeres maintained via ALT or telomerase. Within 24 h of ATR inhibition, cells with short but not long telomeres displayed chromosome bridges and underwent cell death, indicating a selective dependency on ATR for chromosome stability. Collectively, our work provides a resource to identify links between the mode of telomere maintenance and drug sensitivity in osteosarcoma and indicates that telomere length predicts ATR inhibitor sensitivity in cancer.
Insights
Osteosarcoma cancer cells use telomere maintenance mechanisms (TMMs) to survive. Short telomeres predict sensitivity to ATR inhibitors, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cancers utilize telomere maintenance mechanisms (TMMs) to evade senescence and apoptosis.
- Telomere maintenance can occur via telomerase or alternative lengthening of telomeres (ALT).
- The specific TMM employed may impact cancer evolution and therapeutic strategies.
Purpose of the Study:
- To investigate TMMs in osteosarcoma cell lines.
- To correlate TMMs and telomere length with drug sensitivity.
- To identify potential therapeutic vulnerabilities based on telomere maintenance.
Main Methods:
- Analysis of TMMs (telomerase vs. ALT) in 17 osteosarcoma cell lines.
- Categorization of cell lines based on TMM and telomere length (long, short, or excessive).
- Assessment of sensitivity to ataxia telangiectasia and Rad3-related (ATR) inhibitors.
Main Results:
- Osteosarcoma cell lines were classified into ALT-positive, ALT-negative with long telomeres (LT), and ALT-negative with short telomeres (ST).
- ST cell lines exhibited hypersensitivity to ATR inhibitors (AZD-6738, VE-822, BAY-1895344) compared to LT or ALT-positive lines.
- ATR inhibition in ST cells led to chromosome bridges and cell death, indicating a dependency on ATR for stability.
Conclusions:
- Telomere length is a predictive biomarker for ATR inhibitor sensitivity in osteosarcoma.
- Short telomeres in osteosarcoma confer a selective dependency on ATR for chromosome stability.
- This study provides a framework for linking TMMs to drug sensitivity in osteosarcoma.
More Related Videos
Related Concept Videos
Replicative Cell Senescence
Targeted Cancer Therapies
There are several types of targeted therapies against...
DNA Damage can Stall the Cell Cycle

